• Blog
  • Hemophilia A And B Therapeutics Materials Market Report

    Hemophilia A And B Therapeutics Materials Market Report

    Hemophilia A And B Therapeutics Materials Market Report
    Report code - SR1517 Delivery - 2 Weeks
    Get Free Sample |
    Hemophilia A and B Therapeutics Materials Market Trends, Dynamics & Market Insights
    See more...

    Market Insights

    The Hemophilia A and B Therapeutics Materials Market is projected to grow from USD xx billion in 2020 to USD xx billion by 2026 at a CAGR of around x% during the forecast period.

    Figure: Hemophilia A and B Therapeutics Materials Market Size, 2020-2026 (USD Billion)

    Hemophilia-A-and-B-Therapeutics-Materials-Market-Forecast

    Wish to get a free sample? Register Here

    What is hemophilia?

    Hemophilia can be defined as a medical condition in which the ability of the blood to clot is severely reduced which causes the sufferer to bleed severely. Hemophilia is mainly caused by a hereditary lack of a coagulation factor, most often factor VIII. The drugs used to treat Hemophilia A and B include desmopressin, octocogalfa, nonacogalfa and others. 

    Key Players

    Key players operating in the Hemophilia A and B Therapeutics Materials market are-

    • Eagle Biologics, Inc. (US)
    • Spark Therapeutics, Inc. (US)
    • Alnylam Pharmaceuticals Inc. (US)
    • Sangamo Therapeutics, Inc. (US)
    • Novo Nordisk A/S (Denmark)
    • Shire plc (US)
    • The Chugai Pharmaceutical Co., Ltd. (Japan)
    • Bayer AG (Germany)
    • CSL Behring (US)
    • Pfizer Inc. (US).

    Market Dynamics

    The growth of the Hemophilia A and B therapeutics materials market is primarily driven by increasing incidences of blood disorders. Rising initiatives aimed at creating awareness among consumers regarding the prevalence of blood-related diseases are likely to drive the market growth further. In addition to this, increasing investment in research and development activities to develop novel drugs is likely to create lucrative opportunities for the players operating in the global Hemophilia A and B therapeutics materials market in the coming years.

    Segments' Analysis

    End-Use Trends

    By end-use, the Hemophilia A and B therapeutics materials market has been bifurcated into dental clinics, hospitals, and ambulatory surgical centers. The hospital's segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to the presence of established healthcare infrastructure and professional staff.

    Regional Trends

    By region, the North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to the high demand for advanced drugs to treat Hemophilia coupled with the presence of key market players such as Eagle Biologics, Inc. (US) and Spark Therapeutics, Inc. (US). The market growth in Asia-Pacific is expected to be driven by rising consumer awareness related to blood disorders.

    COVID-19 Impact on Hemophilia A and B Therapeutics Materials Market

    The covid-19 outbreak posed significant challenges across verticals worldwide. It impacted the growth of the Hemophilia A and B therapeutics materials market negatively as the therapeutic procedures/treatment for diseases other than covid-19 declined due to fear of coronavirus infection. Also, supply chain disruptions due to the imposition of lockdown affected the product availability on time and thus, affected the market growth. 

    Critical Questions Answered in the Report

    • What are the key trends in the Hemophilia A and B Therapeutics Materials market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the Hemophilia A and B Therapeutics Materials market?
    • What are the key strategies adopted by the major vendors to lead in the Hemophilia A and B Therapeutics Materials market?
    • What is the market share of the top vendors?

    Get the full scope of the report. Register Here

    Target Audience

    Here is the list of the group of customers that the hemophilia A and B therapeutics materials market hopes to have the greatest opportunity to convert-

    • Hemophilia A and B therapeutics materials distributors
    • Hemophilia A and B therapeutics materials suppliers
    • Hemophilia A and B therapeutics materials manufacturers
    • Logistics organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Eagle Biologics, Inc. (US), Spark Therapeutics, Inc. (US), Alnylam Pharmaceuticals Inc. (US), San-gamo Therapeutics, Inc. (US), Novo Nordisk A/S (Denmark), Shire plc (US), The Chugai Pharma-ceutical Co., Ltd. (Japan), Bayer AG (Germany), CSL Behring (US) and Pfizer Inc. (US) are among the key players in the hemophilia A and B therapeutics materials market.

    Increasing incidences of blood disorders is the prime factor driving the growth of hemophilia A and B therapeutics materials market.

    The hospital's segment is expected to register significant growth in the hemophilia A and B therapeutics materials market in the coming years.

    North America accounted for the largest share in the hemophilia A and B therapeutics materials market in 2020.

    Hemophilia A and B therapeutics materials distributors, Hemophilia A and B therapeutics materials suppliers, Hemophilia A and B therapeutics materials manufacturers, Logistics organizations, Government bodies are the target audience in the hemophilia A and B therapeutics materials market.